Shelton Capital Management purchased a new position in PAREXEL International Corporation (NASDAQ:PRXL) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 4,006 shares of the medical research company’s stock, valued at approximately $348,000.

Other large investors have also added to or reduced their stakes in the company. Public Employees Retirement System of Ohio grew its stake in shares of PAREXEL International Corporation by 4.5% in the first quarter. Public Employees Retirement System of Ohio now owns 1,713 shares of the medical research company’s stock worth $108,000 after purchasing an additional 73 shares in the last quarter. Invictus RG bought a new position in shares of PAREXEL International Corporation in the first quarter worth $158,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of PAREXEL International Corporation by 10.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,986 shares of the medical research company’s stock worth $173,000 after purchasing an additional 180 shares in the last quarter. Advisor Group Inc. grew its stake in shares of PAREXEL International Corporation by 75.1% in the second quarter. Advisor Group Inc. now owns 2,000 shares of the medical research company’s stock worth $173,000 after purchasing an additional 858 shares in the last quarter. Finally, BlueCrest Capital Management Ltd bought a new position in shares of PAREXEL International Corporation in the first quarter worth $202,000. 87.45% of the stock is owned by institutional investors.

Several brokerages recently weighed in on PRXL. Zacks Investment Research raised PAREXEL International Corporation from a “hold” rating to a “buy” rating and set a $98.00 target price for the company in a research note on Thursday, August 31st. BidaskClub cut PAREXEL International Corporation from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Barclays PLC cut PAREXEL International Corporation from an “overweighr” rating to an “equal weight” rating and set a $87.00 target price for the company. in a research note on Tuesday, June 20th. Jefferies Group LLC reaffirmed a “hold” rating and set a $88.10 target price on shares of PAREXEL International Corporation in a research note on Wednesday, June 21st. Finally, Raymond James Financial, Inc. raised PAREXEL International Corporation from an “underperform” rating to a “mkt perform” rating in a research note on Tuesday, June 20th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $75.92.

TRADEMARK VIOLATION WARNING: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.thecerbatgem.com/2017/10/13/4006-shares-in-parexel-international-corporation-prxl-acquired-by-shelton-capital-management.html.

Shares of PAREXEL International Corporation (NASDAQ:PRXL) opened at 88.08 on Friday. PAREXEL International Corporation has a one year low of $51.16 and a one year high of $88.10. The stock has a market capitalization of $4.50 billion, a P/E ratio of 42.76 and a beta of 0.77. The stock’s 50 day moving average price is $87.85 and its 200 day moving average price is $79.27.

PAREXEL International Corporation (NASDAQ:PRXL) last issued its quarterly earnings results on Monday, August 28th. The medical research company reported $1.02 EPS for the quarter, beating analysts’ consensus estimates of $0.94 by $0.08. The company had revenue of $557.20 million for the quarter, compared to analyst estimates of $537.59 million. PAREXEL International Corporation had a return on equity of 28.98% and a net margin of 4.49%. During the same period in the previous year, the company posted $0.94 earnings per share. On average, analysts forecast that PAREXEL International Corporation will post $4.06 EPS for the current year.

PAREXEL International Corporation Company Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Want to see what other hedge funds are holding PRXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PAREXEL International Corporation (NASDAQ:PRXL).

Institutional Ownership by Quarter for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Stock Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related stocks with our FREE daily email newsletter.